Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Clin Immunol. 2011 Aug 23;141(2):205–217. doi: 10.1016/j.clim.2011.08.004

Figure 6. Histamine receptor blockage does not decrease anti-FcεR1 mediated delay of diabetes onset.

Figure 6

(A) Stomach pH from animals that were treated for 2 weeks with the histamine receptor blockers cimetidine and fexofenidine (5 animals per group). (B) Representative pictures of mice that were injected i.v. with toluidine blue following challenge with anti-FcεR1 (left ear) and IgG control (right ear). The bottom mouse was treated with fexofenidine, a histamine receptor 1 blocker, whereas the top mouse is an untreated control. (C) Blood glucose levels and (D) percentages of NOD mice with diabetes in the setting of continuous administration of histamine receptor blockers (anti-HR1/2) and treatment with weekly injections of 50 μg anti-FcεR1 or IgG control antibody. Shown are the results from two independent experiments with a total of 10 mice per group. Error bars denote SEM. Statistical significance between groups was assessed by the Mann-Whitney test (*<0.05).